Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings for $8.88 billion in cash to expand its clinical‑trial data and endpoint services. The deal aims to combine Thermo Fisher’s global lab and life‑science capabilities with Clario’s endpoint data and patient‑centric trial platforms. Clario supports a large share of trial endpoints used in recent FDA approvals; Thermo Fisher says the acquisition will deepen its clinical insights and accelerate sponsors’ ability to generate regulatory‑grade evidence. Management projects the acquisition to enhance integrated solutions across trial design, execution and data capture. The transaction signals ongoing consolidation as pharma and biotech seek vertically integrated clinical data providers to shorten development timelines and improve regulatory submission quality. Teams expect regulatory review and customary closing conditions before the deal completes.